ACF reduced CML development in vivo. CML mice were treated daily for 10 days with ACF or placebo and euthanized after 1 additional day. (A) Spleen weight; dotted line: non-CML mice. Data are mean ± S.D. of 8 mice per experimental variant; **P ≤ .01. (B) Hematoxylin-stained lung sections (original magnification ×40) from 2 representative mice per experimental variant (scale bar, 25 µm). (C) Total PB WBCs. Data are mean ± S.D. from 8 mice per experimental variant; **P ≤ .01. (D) Percentage of GFP⁺ (leukemic) or GFP⁻ (nonleukemic) myeloid cells (Gr-1⁺) in PB. Plots show data from 1 representative mouse per experimental variant. Means ± S.D. from 8 mice per experimental variant are reported inside the plots.